## Abstract These are the characteristics and key findings for a Cochrane review, published in this issue of EBCH, first published as: Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. __Cochrane Database of Systematic Re
Characteristics and key findings for ‘Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants’
✍ Scribed by Elvira van Dalen; Martin Offringa; Leontien Kremer
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 54 KB
- Volume
- 1
- Category
- Article
- ISSN
- 1557-6272
- DOI
- 10.1002/ebch.63
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
These are the characteristics and key findings for a Cochrane review, published in this issue of EBCH, first published as: Shah SS, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004213. DOI: 10.1002/14651858.CD004213.pub2.
Further information for this Cochrane review is available in this issue of EBCH in the accompanying EBCH Summary and Expert Commentary articles. Copyright © 2006 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract ## Background A patent ductus arteriosus (PDA) complicates the clinical course of preterm infants, increasing their risks of developing chronic lung disease (CLD), necrotizing enterocolitis (NEC), and intraventricular hemorrhage (IVH). Indomethacin is used as standard therapy to close